Novo Nordisk and Chip Ganassi Racing Teams announced that the two organizations have entered into a multi-year extension of their partnership sponsoring No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the IZOD IndyCar Series. Charlie Kimball is the first licensed driver with type 1 diabetes in the history of INDYCAR to race at the highest level of the series. This agreement comes after a Kimbal’s successful first year in the IZOD IndyCar Series which included two top-10 finishes at Birmingham and New Hampshire and a 13th place in his debut at the Indianapolis 500.
Diagnosed in 2007, Kimball monitors his blood sugar before, during and after each race. Charlie also uses the Novo Nordisk insulin Levemir® (insulin detemir [rDNA origin] injection) and NovoLog® (insulin aspart [rDNA origin] injection) to help manage his diabetes, administering it with a prefilled insulin pen device called FlexPen®.
The new agreement begins with the 2012 IZOD IndyCar season and the launch of a new IZOD IndyCar Series car that replaces the race car introduced in 2003. Next year also marks the fourth consecutive year of partnership between Novo Nordisk and Kimball. Following two years of sponsorship of Kimball in the Firestone Indy Lights Series, Novo Nordisk partnered with Chip Ganassi Racing to form Novo Nordisk Chip Ganassi Racing and in December 2010, became the title sponsor of Charlie in his IndyCar rookie season.
Novo Nordisk has also been actively involved in providing information about diabetes awareness at INDYCAR events through the Drive the Switch device awareness program and the award-winning Race with Insulin™ campaign. The team extension also retains the company’s primary sponsorship of Kimball’s race car, race suit and other branding opportunities. Kimball will continue to make appearances on behalf of Novo Nordisk throughout the term of the agreement.
For more information about Novo Nordisk Chip Ganassi Racing, visit www.
